Skip to Navigation Skip to Posts Skip to Content

Aya Enkoji

1 post

Aya Enkoji

Expanding HER2-Targeted Therapy: Trastuzumab Deruxtecan in HR⁺, HER2-Low and Ultralow Metastatic Breast Cancer

Subscribe for Updates

Never miss a new article or vital healthcare update.

Sign up Now